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Kinase inhibitorshave limitedsuccess in cancer treat-
ment because tumors circumvent their action. Using
a quantitative proteomics approach, we assessed
kinome activity in response to MEK inhibition in
triple-negative breast cancer (TNBC) cells and genet-
ically engineered mice (GEMMs). MEK inhibition
caused acute ERK activity loss, resulting in rapid
c-Myc degradation that induced expression and acti-
vation of several receptor tyrosine kinases (RTKs).
RNAi knockdown of ERK or c-Myc mimicked RTK
induction by MEK inhibitors, and prevention of pro-
teasomal c-Mycdegradationblockedkinome reprog-
ramming. MEK inhibitor-induced RTK stimulation
overcame MEK2 inhibition, but not MEK1 inhibition,
reactivating ERK and producing drug resistance.
The C3Tag GEMM for TNBC similarly induced RTKs
in response to MEK inhibition. The inhibitor-induced
RTK profile suggested a kinase inhibitor combina-
tion therapy that produced GEMM tumor apoptosis
and regression where single agents were ineffective.
This approach defines mechanisms of drug resis-
tance, allowing rational design of combination thera-
pies for cancer.INTRODUCTION
Kinase-targeted cancer therapies can fail when tumor cells
circumvent the action of a single agent, facilitating therapeuticresistance. Acquired or selected mutations can decrease affinity
for kinase inhibitors, but resistance also develops through alter-
nate routes of kinase pathway activation. For example, RTK
upregulation has been observed following targeted inhibition of
selective kinases (Chandarlapaty et al., 2011; Johannessen
et al., 2010; Nazarian et al., 2010; Villanueva et al., 2010);
this kinome reprogramming circumvents inhibition of proto-
oncogenic kinases. Alternatively, genomic loss of PTPN12 phos-
phatase expression similarly causes activation of multiple
tyrosine kinases (Sun et al., 2011). Thus, dynamic and system-
wide changes in multiple kinases can occur in tumor cells
following pharmacological or progressive genetic perturbations.
An understanding of these kinome responses and the mecha-
nisms by which they occur will be key in determining how to
abrogate therapeutic resistance. With more than 130 kinase-
specific inhibitors currently in phase 1–3 clinical trials, devel-
oping combination therapies that are relevant for molecularly
defined cancer subtypes is a highly tractable goal. However,
rational design of kinase inhibitor combinations requires an over-
all knowledge of kinome activity and response, not just a simple
measure of an inhibitor’s effect on one or two kinase pathway
components. Currently, there is no optimal discovery mecha-
nism to define the entire kinome and its dynamic activity. Such
a technique could globally assess tumor kinome response to
small molecule inhibitors and suggest more effective combina-
tion therapies.
To meet this challenge, we developed a chemical proteomics
approach using multiplexed kinase inhibitor beads and mass
spectrometry (MIB/MS) to define and quantitate the activity
and drug responsiveness of a significant percentage (50%–
60%) of the expressed kinome. We applied this technique to
triple-negative breast cancer cell lines, preclinical tumor models,
and human tumors. Analysis of patient TNBC showed activatedCell 149, 307–321, April 13, 2012 ª2012 Elsevier Inc. 307
RAF-MEK1/2-ERK1/2 signaling, supporting MEK as a target in
TNBC. Pharmacologic MEK inhibition in TNBC cell lines and
GEMM tumors resulted in rapid kinome reprogramming through
the induced expression and activation of multiple Tyr and
Ser/Thr kinases that bypassed the initial MEK-ERK inhibition.
Alterations in virtually every Tyr and Ser/Thr kinase family were
observed. The mechanism of this kinome reprogramming in-
volved the proteolytic degradation of c-Myc following MEK1
and MEK2 inhibition, which resulted in increased expression
and activity of RTKs. MIB/MS analysis showed that reprog-
rammed kinase activation overcame MEK2 (but not MEK1)
inhibition, leading to therapeutic resistance. The MEK inhibitor
kinome response signature allowed us to predict and test the
efficacy of a novel small molecule kinase inhibitor combination.
The combination synergistically inhibited TNBC cell line prolifer-
ation and caused apoptosis and tumor regression in the C3Tag
GEMM of basal-like/claudin-low TNBC.
RESULTS
Kinome Profiling of TNBC
TNBC clinical trials of single kinase inhibitors have largely failed,
consistent with drug-induced activation of alternative survival
signaling pathways. Figure 1A outlines our strategy to interrogate
kinome dynamics with the goal of defining endpoints leading to
rational design of combination therapies. RNA-seq defined
the transcript-level expressed kinome, and affinity capture of
endogenous kinases followed by quantitative mass spectrom-
etry measured kinome activity profiles in tumors and cells. The
proteomic assessment was used to define the kinome response
to targeted inhibition of kinases. RNAi tested growth and survival
functions of the kinases activated in response to inhibitors, and
the cumulative results were used to rationally predict kinase
inhibitor combinations to test in models of TNBC.
RNA-seq defined the kinome transcript expression profile of
a patient’s claudin-low breast tumor and two claudin-low
TNBC lines, SUM159 and MDA-MB-231. More than 400 of the
518 human protein kinases were expressed in the claudin-low
human TNBC tumor and cell lines (Figure 1B). Approximately
10% of the kinases expressed in the claudin-low patient tumor
were unique compared to the claudin-low cell lines, undoubtedly
due to the tumor’s complex cellular composition (Table S1
available online). Themajority of expressed kinases are common
between tumor and claudin-low cell lines, suggesting that
interrogating the cellular kinome response to inhibitors will be
relevant to patient tumors.
Profiling kinase activity in tumors and cell lines was carried out
using multiplexed inhibitor beads (MIBs), which consist of mix-
tures of Sepharose beads with covalently immobilized, linker-
adapted kinase inhibitors of moderate selectivity for different
kinases (Bisindoylmaleimide-X, SB203580, Dasatinib, and
Lapatinib) and relatively broad pan-kinase inhibitors (VI16832,
Purvalanol B, and PP58) (Figure S1A) (Daub et al., 2008). Kinase
capture is reproducible and is a function of kinase expression,
the affinity of kinases for the immobilized inhibitors, and the
activation state of the kinase (Bantscheff et al., 2007). Acute
changes in activation-dependent binding were demonstrated
by the increased binding of MAPK pathway kinases in EGF-308 Cell 149, 307–321, April 13, 2012 ª2012 Elsevier Inc.stimulated cells and by the increased retention of Tyr kinases
from cells treated with the Tyr phosphatase inhibitor pervana-
date (Figures S1B and S1C). Our data showed that MIBs capture
themajority of the expressed kinome estimated by RNA-seq and
detect altered kinome activity profiles in response to stimulus or
clinical kinase inhibitors.
UsingMIBs andmass spectrometry (MIB/MS), we have cumu-
latively sequence identified more than 320 kinases from cell lines
and tumors (Table S2). MIB/MS profiling of an invasive ductal
carcinoma breast tumor and two claudin-low cell lines identified
50%–60% of the expressed kinome (Figures 1C–1E and
Tables S1 and S3). Kinases from all major kinome subfamilies
were captured, with a large percentage representing the untar-
geted kinome (Fedorov et al., 2010). iTRAQ labeling of digested
MIB elutions allowed quantitative profiling of kinases in patient
invasive ductal carcinoma compared to adjacent uninvolved
mammary tissue (Figure 1F). Of the kinases detected, there
was a general increase in MIB binding of tumor kinases, sug-
gesting escalated kinome activity in the tumor compared to
uninvolved mammary tissue. For example, the RAF-MEK-ERK
pathway is increased in MIB binding in the tumor relative to
control tissue, consistent with ERK activity being a driver for
TNBC proliferation. Immunoblots confirmed the activation of
RAF-MEK-ERK signaling in the patient invasive ductal carci-
noma (Figure 1G). RTK arrays further revealed Tyr phosphory-
lated RTKs in two human tumors, which showed phosphoryla-
tion of EGFR, HER2, PDGFRb, CSF1R, RON, and EPHB2
(Figure 1H). Although our data pointed to the potential impor-
tance of Tyr-phosphorylated EGFR and PDGFRb in patient
TNBC, clinical trials targeting these RTKs have largely failed
(Bianchi et al., 2009; Finn et al., 2009). The failure of single-agent
RTK inhibitors in TNBC is consistent with drug-induced activa-
tion of multiple kinases or compensatory tumor kinome re-
sponses. Because many expressed RTKs drive ERK activation,
we profiled claudin-low breast cancer cells after MEK inhibition
(e.g., AZD6244 currently in clinical trials) to determine whether
dynamic kinome reprogramming occurs. Our goal was to
define kinome alterations that would suggest a more effective,
rationally designed combination therapy.
Reprogramming the Kinome in Response to MEK
Inhibition
MEK inhibitors AZD6244 or U0126 inhibited growth of SUM159
(Figure 2A) and MDA-MB-231 cells (Figure S2A). ERK remained
inhibited after 4 hr of MEK inhibitor treatment, whereas MEK
phosphorylation was enhanced (Figure 2B). Inhibitor treatment
for 24 hr resulted in reactivation of ERK, demonstrating that
both lines overcame the initial MEK inhibition (Figures 2B
and S2B). Phosphoproteomic analysis revealed loss of ERK-
mediated feedback regulation of both BRAF and MEK1 (Fig-
ure 2C). Reduced phosphorylation of negative feedback sites
on BRAF and MEK1 indicate escape from the suppressive feed-
back regulation on the ERK pathway (Ritt et al., 2010). Analysis
of MIB-isolated protein kinases identified 52 peptides with
decreased and 59 peptides with increased phosphorylation,
whereas the phosphorylation status of 365 phosphopeptides
was unchanged after MEK inhibition (Figure S2C and Table S3).
The majority of these phosphorylation sites were Ser, Thr-, and
Figure 1. Kinome Profiling of TNBC Reveals Elevated ERK Signaling
(A) Experimental strategy for the rational design of kinase inhibitor combination therapies. To define kinome inhibitor response signatures, expression profiling is
integrated with kinase affinity capture and MS quantitative assessment of the activation state of the kinome. RNAi is used to analyze kinase function in survival
response to inhibitors.
(B) Venn diagram shows number of expressed kinases defined by RNA-seq across patient TNBC and MDA-MB-231 and SUM159 cell lines. See Table S1 for
normalized read count transcript expression profiles.
(C) Venn diagram shows number of kinases captured and identified byMIB-based proteomics across patient-sample TNBC andMDA-MB-231 and SUM159 cell
lines. MIB/MS captures 50%–60% of the expressed kinome as defined by RNA-seq. See Table S2 for MS identifications of protein kinases.
(D) Distribution and (E) overlap of expressed and MIB-bound kinases across patient-sample TNBC and MDA-MB-231 and SUM159 cell lines.
(F) RAF-MEK-ERK pathway activated in patient TNBC tumors. Quantitative comparison of patient TNBC to matched uninvolved mammary tissue using MIB/MS.
The line graphs show iTRAQ-determined quantitative changes in MIB binding as a ratio of tumor/uninvolved. Ratio < 1 denotes decreased MIB binding, and > 1
denotes increased MIB binding of kinase in tumor versus control tissue.
(G) Immunoblotting confirms an activated RAF-MEK-ERK pathway in TNBC cell lines and TNBC patient samples.
(H) RTK array analysis of patient TNBC tumors reveals multiple Tyr-phosphorylated RTKs, including EGFR and PDGFRb.
See also Figure S1 and Tables S1 and S2.
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Figure 2. Reprogramming of the Kinome in Response to MEK Inhibition
(A) Growth inhibition of SUM159 cells in response to AZD6244 or U0126. Triplicate experiments ± SD.
(B) Reactivation of MEK and ERK in the continued presence of 5 mM AZD6244 shown by western blot.
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Pro-directed Ser/Thr sites, but pTyr changes were also included,
suggesting a broad change in kinome activity in response to
AZD6244.
We next used MIB/MS to profile the SUM159 kinome
response after exposure to AZD6244 (Figure 2D). MEK inhibition
resulted in time-dependent MIB binding changes for more than
140 kinases, including cell-cycle regulatory kinases, MAPK
pathway kinases, RTKs, cytosolic Tyr kinases, and other Ser/
Thr kinases. Figure 2E highlights the MIB binding dynamics for
MAPK component kinases during the time course of MEK inhib-
itor response in SUM159 cells. At 4 hr of AZD6244 treatment,
both MEK1 and MEK2 are inhibited, as measured by loss of
MIB binding. However, whereas MEK1 binding remains largely
inhibited, MEK2 binding to MIBs increases at 12 hr of treatment
and by 24 hr was similar to control cells, indicating a return of
MEK2 activity. In parallel to restored MEK2 binding to MIBs,
RAF1 and ERK1 binding to MIBs increases over the time course
of AZD6244 treatment, correlating with activation of these
kinases. We used RNAi for each kinase in the MAPK pathway
to determine whether knockdown had a differential growth affect
in response to MEK inhibition (Figure 2F). RNAi knockdown
shows that loss of MEK2 and ERK1 inhibited SUM159 cell
growth in the presence of MEK inhibitor, whereas MEK1 knock-
down did not enhance growth inhibition. Taken together, these
data indicate that MEK2 and ERK1 can escape from inhibition
by AZD6244, suggesting a critical role for MEK2/ERK1 in
SUM159 growth and survival during AZD6244 treatment.
Figures 2G and 2H show a 21 kinase signature defining
a reprogrammed kinome in response to MEK inhibitors. This
signature shows a loss of cyclin-dependent kinases, consistent
with growth inhibition, and increased ERK binding to MIBs, indi-
cating escape from MEK inhibition. RTKs, including AXL, DDR1
and PDGFRb; cytosolic Tyr kinases FAK2 and JAK1; and the
Ser kinase ACVR1, all showed increased MIB binding. Whereas
MDA-MB-231 cells have a somewhat less robust kinome
response to AZD6244, they displayed a significant kinome re-
programming that included a strong increase in PDGFRb binding
to MIBs (Figure S2D).
RTK arrays confirm the increased Tyr phosphorylation of
multiple RTKs, including PDGFRb and AXL in response to MEK
inhibition (Figures 2I and S2E). In SUM159 cells, AZD6244
also significantly increased Tyr phosphorylation of VEGFR2
and RET. The AZD6244 response of SUM159 cells is dose(C) Loss of ERK-regulated feedback of the RAF-MEK-ERK pathway and downst
kinome phosphorylation analyzed by MIB/MS.
(D) Activation and repression of the kinome in response to 5 mM AZD6244 in SU
binding as a ratio of AZD6244/DMSO. Ratio < 1 denotes decreased and > 1 den
(E) MEK2 and ERK1 escape AZD6244 inhibition. MIB/MS binding profile of RAF-M
5 mM U0126 for 24 hr.
(F) MEK2 and ERK1 promote survival following MEK inhibition. siRNA knockdown
not MEK1, inhibits growth in the presence of U0126.
(G) Kinome response signature for MEK inhibition in SUM159 cells. Triplicate MIB
DMSO. Error bars represent mean ± SD where kinases are significant at FDR of
(H) Kinome map of AZD6244 response (blue, inhibited; red, induced) as determin
(I) Increased Tyr phosphorylation of RTKs in response to MEK inhibition. SUM15
(J) Dose-dependent RTK reprogramming in response to AZD6244. Dose-depend
determined by western blot.
See also Figure S2 and Table S3.dependent (Figure 2J), as PDGFRb and VEGFR2 show increased
RTK phosphorylation and expression with increasing AZD6244.
These results demonstrate that a significant number of kinases
were induced in response to MEK inhibition. Relevant to the
changes in the kinome to MEK inhibition, Figure S2F lists the
40 highest expressed kinase transcripts of a patient claudin-
low tumor. Of these 40 kinases, 14 (24%) were dynamically regu-
lated in SUM159 and/or MDA-MB-231 cells in response to
AZD6244, suggesting that patient tumors could have a similar
kinome reprogramming in response to targeted kinase inhibition.
MEK Inhibition Deregulates Transcription, Expression,
and Activation of RTKs
Figures 3A and S3A define the time course of kinome reprogram-
ming to AZD6244 in SUM159 and MDA-MB-231 cells. MEK and
ERK were rapidly inhibited, allowing accumulation of MKP3, the
MAPK phosphatase that inactivates ERK (Marchetti et al., 2005).
IncreasedMKP3 expression combinedwith AZD6244 to strongly
suppress ERK activity, but MKP3 protein was lost as MAPK
pathway activity returned. Over time, VEGFR2, PDGFRb, and
DDR1 expression was increased with AZD6244 treatment, as
was the phosphorylation of HER3 and AXL. qRT-PCR analysis
of SUM159 (Figure 3B) and MDA-MB-231 (Figure S3B) cells
treated with AZD6244 demonstrated elevated RNA levels for
several of these RTKs, including DDR1/2, PDGFRb, VEGFR2
(SUM159 only), and HER2/3. Analysis of cytokine RNA expres-
sion showed EGF, Gas6, PDGFB, and PDGFD induction, indi-
cating the establishment of autocrine/paracrine loops for RTK
activation (Figures 3C and S3C). RTK arrays further showed
a time-dependent increase in Tyr phosphorylation of PDGFRb,
VEGFR2, and HER2/3 (DDR1/2 are not on the array) (Figure 3D).
PDGFRb, whose RNA and protein expression was induced in
response to AZD6244, was phosphorylated at Tyr 751, 857,
and 1009—sites that are required for PDGFRb activation and
recruitment of PI3K and PLCg (Figure 3E).
After 30 days of continuous exposure to AZD6244, SUM159
cells have become significantly resistant to MEK inhibitor-
induced growth arrest (Figure 3F). Expression of cyclins A2
and B1 have recovered, consistent with increased proliferation
(Figure S3D). The AZD6244-resistant cells (SUM159-R, grown
continuously in 5 mM AZD6244) continue to have a reprog-
rammed kinome in which PDGFRb and VEGFR2 exhibited both
increased expression and Tyr phosphorylation, and AXL showedream signaling. SUM159 cells were treated with 5 mM AZD6244 for 12 hr and
M159 cells. Line graphs show iTRAQ-determined quantitative changes in MIB
otes increased MIB binding of kinases in treated versus control cells.
EK-ERK from SUM159 cells treated with 5 mM AZD6244 for 4, 12 and 24 hr or
of MAPK signaling components in SUM159 cells shows that loss of MEK2, but
/MS runs of SILAC-labeled SUM159 cells ± 5 mMAZD6244 or U0126 relative to
0.05.
ed by MIB/MS and RTK arrays.
9 cells were treated with 5 mM AZD6244 for 24 hr and analyzed by RTK array.
ent induction of RTK expression and activity in 24 hr treated SUM159 cells was
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Figure 3. AZD6244-Induced Kinome Reprogramming Is Target Specific and Involves Rapid, Stable Transcriptional Upregulation of RTKs and
Cytokines
(A) AZD6244 treatment initially causes ERK inhibition and accumulation of MKP3. With prolonged AZD6244 treatment, increased RTK expression and
downstream survival signaling coincides with the reactivation of RAF-MEK-ERK signaling.
(B and C) Time-dependent increase in (B) RTK and (C) cytokine gene expression in SUM159 cells after AZD6244 treatment, determined by qRT-PCR.
(D) Prolonged treatment of SUM159 cells with AZD6244 leads to stable upregulation of RTKs. SUM159 cells were treated with DMSO or AZD6244 for 4–72 hr or
30 days, and RTK tyrosine phosphorylation was determined by RTK antibody arrays.
(E) Treatment with AZD6244 enhances phosphorylation of PDGFRb at multiple sites, including the activation loop.
(F) Generation of AZD6244-resistant SUM159 cells following stable treatment with AZD6244. Increased cell growth of SUM159-R cells compared to SUM159
cells treated with AZD6244 for 72 hr determined by cell counts (*p < 0.001).
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increased Tyr phosphorylation (Figures 3D and 3G). Activation of
these RTKs is accompanied by increases in phosphorylated
AKT, RAF, p70 S6 kinase, MEK, ERK, and RSK1, showing that
the cells overcame MEK inhibition by RTK activation of the
ERK, AKT, and mTOR pathways (Figure 3G).
These findings indicate that targeted MEK inhibition signifi-
cantly alters the activity of multiple kinases. It was therefore
important to determine whether the changes in kinase activity
were specific for MEK inhibition or a function of growth arrest.
BEZ235 is a dual PI3K/mTOR inhibitor that strongly inhibits
SUM159 cell growth (Figure S3E). BEZ235 inhibited p70 S6
kinase activity, consistent with mTOR inhibition, but had no
effect on the ERK pathway (Figure S3F). We compared the
SUM159 kinome responses to BEZ235 and AZD6244 to deter-
mine whether kinome reprogramming was target specific or a
function of growth arrest. Whereas AZD6244 induced PDGFRb,
VEGFR2, and AXL phosphorylation, BEZ235 treatment did not
change the RTK phosphorylation profile except for increased
phosphorylation of INSR, IGF1R, and AXL (Figure 3H). MIB/MS
confirmed that AZD6244 altered the kinome differently from
BEZ235, indicating that drug-induced kinome reprogramming
is target specific (Figure S3G).
MEK-ERK Inhibition Induces c-Myc Degradation,
Leading to RTK Reprogramming
ERK phosphorylates the transcription factor c-Myc at Ser62
and stabilizes c-Myc protein by preventing its proteasomal
degradation (Sears et al., 2000). Treatment of both SUM159
and MDA-MB-231 cells with AZD6244 caused rapid loss of
c-Myc protein and mRNA (Figures 4A, 4B, and S4A). This
AZD6244-mediated repression of c-Myc protein and transcript,
along with reduced phosphorylation of c-Myc at Ser62 (Figures
4B and S4A–S4C), resulted in decreased Myc-Max hetero-
dimerization that is required for Myc transcriptional regula-
tion (Figure 4C) (Marampon et al., 2006; Wierstra and Alves,
2008). Despite partial recovery of MEK-ERK activation after
24–72 hr, total c-Myc expression remained repressed in
the continued presence of AZD6244 (Figures 4A–4C and
S4A–S4C).
c-Myc binds the promoter of human pdgfrb (Figure S4D) to
repress PDGFRb expression (Oster et al., 2000). To define the
role of c-Myc loss in the AZD6244 reprogramming response,
we applied RNAi to knockdown expression of c-Myc; the effect
was analogous to the reprogrammed RTK and cytokine
response seen with AZD6244 treatment (Figures 4D, 4E, and
S4E). Similar to the AZD6244 response, knockdown of c-Myc
induced expression of PDGFRb, VEGFR2, and PDGFB and
increased Tyr phosphorylation of PDGFRb, VEGFR2, HER3,
and AXL. RNAi knockdown of ERK1/2 confirmed that ERK inhi-
bition was the primary signal inducing loss of c-Myc mRNA
expression in the AZD6244 reprogramming of the kinome. Dual
ERK1/2 knockdown resulted in reduced c-Myc and increased(G) Maintenance of RTK reprogramming in SUM159-R cells accompanied by incr
DMSO or AZD6244 for 4 hr was compared to SUM159-R cells by western blot.
(H) AZD6244 and BEZ235 are target specific in their reprogramming of kinome res
cells despite similar growth inhibition.
Error bars represent triplicate experiments ± SD. See also Figure S3.PDGFRb expression (Figure S4F). Thus, reprogramming of
RTKs in response to AZD6244 occurs by loss of ERK-mediated
stabilization of c-Myc and the subsequent transcriptional dere-
pression of RTKs and cytokines that are negatively regulated
by c-Myc. BEZ235 inhibition of mTOR and PI3K inhibited cell
growth but did not change ERK activity, c-Myc expression (Fig-
ure S4G), or RTK reprogramming (Figure S3G), confirming the
specificity of MEK-ERK in controlling c-Myc levels.
Proteasomal degradation of c-Myc lacking Ser62 phosphory-
lation triggers AZD6244-induced kinome reprogramming. Ex-
pression of a nondegradable c-Myc(T58A) mutant in SUM159
cells significantly blocked AZD6244-mediated induction of
PDGFRb, DDR1, and VEGFR2 (Figures 4F and 4G). GSK3b pro-
motes c-Myc degradation, and inhibition of GSK3b stabilized
c-Myc protein to repress the induction of PDGFRb (Figure S4H).
Similarly, treatment of SUM159 or SUM159-R cells with the pro-
teasome inhibitor bortezomib prevented AZD6244-mediated
c-Myc degradation, blocked c-Myc mRNA repression, and in-
hibited the induction of PDGFRb, DDR1, and VEGFR2 (Figures
4H and S4I–S4M). Washout of AZD6244 from SUM159 or
SUM159-R cells led to increased ERK activity, stabilization of
c-Myc expression, and subsequent loss of RTK reprogramming
(Figures 4I and S4N–S4P). Thus, stabilizing c-Myc protein levels
prevented the onset of RTK reprogramming to AZD6244 and
reversed the reprogramming in SUM159-R cells. Taken together,
these findings show that AZD6244-induced c-Myc proteasomal
degradation is responsible for kinome reprogramming and RTK
upregulation.
In SUM159-R cells, c-Myc protein, mRNA levels, and Myc-
Max heterodimers have partially returned due to reactivated
ERK stabilizing c-Myc (Figures 4J, 4K, and S4Q). This correlates
with SUM159-R cells having an increased growth rate compared
to cells acutely treated withMEK inhibitor (Figure 3F). The level of
c-Myc protein, however, is insufficient to completely repress
RTK expression, which remains elevated compared to control
cells but at lower levels than cells treated with AZD6244 for
4–72 hr (Figures 4K and L). A 5-fold increase in AZD6244
concentration inhibited ERK activation in SUM159-R cells (Fig-
ure 4M) because the higher dose of MEK inhibitor more
effectively prevented RTK-stimulated reactivation of MEK-ERK
signaling. As expected, the resulting loss of phospho-c-Myc
S62 and total c-Myc protein led to a corresponding increase in
RTK expression in SUM159-R cells. Of note, the return of phos-
pho-ERK in the continued presence of AZD6244 was insufficient
to completely reverse RTK reprogramming, suggesting that ERK
may not be fully reactivated. This was shown by measuring the
phosphorylation of two ERK substrates, RSK1 and c-Myc, after
only 1 hr of AZD6244 washout from SUM159-R cells (Figure 4N).
Phosphorylation of both substrates and phospho-ERK was
increased, demonstrating further activation of ERK shortly after
the removal of MEK inhibitor. Thus, the combination of persis-
tent c-Myc transcriptional repression and partial MEK-ERKeased survival signaling. Kinome reprogramming in SUM159 cells treated with
ponse. BEZ235 induces a kinase response different than AZD6244 in SUM159
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Figure 4. AZD6244-Mediated Loss of ERK1/2CausesRapidDegradation of c-Myc, Destabilization ofMyc-MaxComplexes, andPromotion of
RTK Expression
(A) Loss of ERK1/2 activity following AZD6244 treatment promotes c-Myc degradation. SUM159 cells were treated with AZD6244 andmonitored by western blot.
(B) Stable suppression of c-Myc RNA levels following AZD6244 treatment. MDA-MB-231 and SUM159 cells were treated with AZD6244 and c-Myc gene
expression determined by qRT-PCR.
(C) Disruption of Myc-Max complexes following AZD6244 treatment. SUM159 cells were treated with AZD6244 for 0, 4, and 72 hr. Nuclear extracts were
immunoprecipitated with anti-Max antibodies and immunoblotted for Myc and Max.
(D) RNAi knockdown of c-Myc using pooled siRNA for 72 hr in SUM159 cells upregulates gene expression of PDGFRb, VEGFR2, and PDGFB, as determined by
qRT-PCR.
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reactivation allows the maintenance of RTK reprogramming,
leading to MEK inhibitor resistance.
RTK Reprogramming Rescues Cells from AZD6244-
Induced Growth Arrest
RNAi knockdown of PDGFRb in SUM159 cells enhanced growth
inhibition by AZD6244 (Figure 5A), indicating that the induction of
RTK signaling was critical for growth and survival of cells in-
hibited by AZD6244. To test the role of additional RTKs in the
rescue response of cells to MEK inhibition, we performed siRNA
knockdown of RTKs found to be transcriptionally induced and/or
Tyr phosphorylated in response to U0126 in SUM159 (Figure 5B)
and MDA-MB-231 cells (Figure S5A). As controls, we used
siRNA to knockdown BRAF, RAF1, and ERK1/2; knockdown of
each pathway member enhanced growth arrest observed with
MEK inhibition (Figures S5A and S5B). Knockdown of PI3K and
AKT produced a greater growth arrest response in SUM159
than MDA-MB-231 cells, consistent with mutant PI3K being a
driver in SUM159 cells. siRNA knockdown of LYN and EPHA2
had no effect on the growth of either cell type in the presence
or absence of MEK inhibitor (LYN and EPHA2 show no change
or loss of MIB binding in response to MEK inhibitor). Though
knockdown of HER2 or HER3 had little effect in SUM159 and
MDA-MB-231 cells, knockdown of AXL, DDR1, DDR2, PDGFRb,
and VEGFR2 each resulted in a strong synthetic lethal-like effect
in the presence of U0126 (Figures 5B, S5A, S5C, and S5D). Thus,
loss of MEK-ERK signaling causes induction of multiple RTKs,
each contributing to the subversion of MEK inhibition.
AZD6244 in Combination with RTK Inhibitors
Our results suggested RTK inhibitors in combination with
AZD6244 could block the growth-promoting activity of the
reprogrammed kinome. Given the repertoire of AZD6244-
activated RTKs, we tested sorafenib and foretinib alone or in
combination with AZD6244 for their ability to inhibit cell growth
(Figures 5C, 5D, S5E, and S5F; see Table S4 for targeted kinases
by each inhibitor). Whereas the two RTK inhibitors were ineffec-
tive as single agents, both were synergistic in inhibiting cell(E) RNAi knockdown of c-Myc upregulates PDGFRb, VEGFR2, and DDR1 express
for 48 hr, and kinome reprogramming was determined by western blot.
(F) Retroviral expression of nondegradable c-Myc(T58A) in SUM159 cells suppres
western blot and quantified by densitometry.
(G) Transcript levels of DDR1, PDGFRb, and VEGFR2 are reduced by the expres
cells were treated for 24 hr and analyzed by qRT-PCR.
(H) Stabilization of c-Myc protein levels by bortezomib prevents AZD6244-mediat
bortezomib alone or in combination for 24 hr. Bortezomib blocked the AZD6244
(I) Removal of AZD6244 results in stabilization of c-Myc protein and reversal of RTK
24 hr of treatment, and cells were grown without AZD6244 for a further 24 hr.
(J) c-Myc protein levels partially return in SUM159-R cells, whereas AZD6244-me
treated with AZD6244 and RTK, and c-Myc levels were compared to SUM159-R
(K) Increased c-Myc RNA levels in SUM159-R cells relative to AZD6244-treated S
and c-Myc gene expression was compared to SUM159-R cells using qRT-PCR
(L) AZD6244-induced RTK expression is maintained at reduced levels in SUM15
treated with AZD6244 for 24 hr or SUM159-R cells relative to DMSO-treated cel
(M) c-Myc stabilized by RTK-mediated ERK activation in SUM159-R cells. RTK r
SUM159-R treated with AZD6244 for 24 hr.
(N) RTK-mediated reactivation of ERK is incomplete in the continued presence of A
and ERK1/2 phosphorylation of c-Myc and RSK1 determined by western blot.
Error bars represent triplicate experiments ± SD. See also Figure S4.growth in combination with AZD6244, with sorafenib being the
most effective. Cell counting assays reinforced the strong syner-
gistic growth arrest of SUM159 cells with the AZD6244/sorafenib
combination (Figure 5E); RTK arrays validated that sorafenib
inhibited Tyr phosphorylation of multiple RTKs induced by
AZD6244 (Figures 5F and S5G). The combination of AZD6244/
sorafenib enhanced the inhibition of ERK1/2, decreased cyclin
D1 levels, and increased expression of the proapoptotic Bim
protein compared to AZD6244 alone, indicating that the cells
were primed for apoptosis (Figures 5G and S5H).
Sorafenib inhibits PDGFRa and b, VEGFR2, and DDR1/2 but is
also an inhibitor of BRAF and RAF. Therefore, we assayed the
action of different RAF inhibitors in combination with AZD6244
to determine whether the effect of sorafenib could be mimicked
by other BRAF/RAF inhibitors (Figures S5I and S5J). The RAF
inhibitor SB590885 inhibited MDA-MB-231 proliferation in com-
bination with AZD6244 to a similar extent as sorafenib, consis-
tent with the role of BRAF activation downstreamof the observed
RTK reprogramming as a driver of the proliferation. RAF inhibi-
tors, but not sorafenib, in combination with AZD6244 actually
stimulated the growth of SUM159 cells (Figure S5I), consistent
with the known activation of wild-type RAF signaling by both
PLX4720 and SB590885. At 250–500 nM, only sorafenib syner-
gistically inhibited growth of SUM159 cells in combination with
AZD6244. Thus, sorafenib in combination with AZD6244 inhibits
growth of SUM159 cells more effectively than BRAF inhibitors by
cotargeting induced RTKs.
SUM159-R cells that have become resistant to AZD6244 rely
on RTK-driven reactivation of ERK for drug resistance. If
a 10-fold higher dose of AZD6244 is used, ERK activity can be
inhibited (Figure 5H). At the 5 mM dose of AZD6244 that was
used to develop SUM159-R cells, the addition of sorafenib in-
hibited ERK activity and cell growth (Figure 5I), confirming that
AZD6244-induced activation of upstream RTKs drives ERK
reactivation. In SUM159-R cells, the combination of low doses
of AZD6244 and sorafenib was similarly effective as high-dose
AZD6244 at inhibiting ERK activation and cell growth (Figures
5H and 5I).ion. SUM159 cells were transfected with deconvolved c-Myc or GAPDH siRNA
ses RTK reprogramming after 24 hr treatment with 5 mMAZD6244, as shown by
sion of c-Myc(T58A) in the presence and absence of 5 mM AZD6244. SUM159
ed kinome reprogramming. SUM159 cells were treated with AZD6244 (5 mM) or
-dependent induction of RTKs as shown by western blot.
reprogramming. AZD6244was removed from themedia of SUM159 cells after
diated RTK reprogramming is reduced but still maintained. SUM159 cells were
cells by western blot.
UM159 cells. SUM159 cells were treated with DMSO or 5 mMAZD6244 for 4 hr,
(*p < 0.001).
9-R cells. qRT-PCR was used to compare gene expression in SUM159 cells
ls.
eprogramming and c-Myc levels were determined by western blot comparing
ZD6244. AZD6244 (5 mM)was removed frommedia of SUM159-R cells for 1 hr
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Figure 5. RTK Inhibition Synergizes to Enhance AZD6244-Induced Growth Arrest
(A) RNAi knockdown of PDGFRb enhances AZD6244-induced growth arrest. PDGFRb knockdown was performed in the presence or absence of 1.25 mM
AZD6244 in MDA-MB-231 and SUM159 for 96 hr, and cell growth was monitored using Cell-Titer Glo.
(B) RNAi knockdown of MEK inhibitor-responsive RTKs in SUM159 cells synergizes with U0126 to inhibit growth. Cell proliferation was determined at 96 hr of
treatment by Cell-Titer Glo.
(C) Cotreatment with AZD6244 and sorafenib synergizes in cell growth inhibition of SUM159 cells, as determined by Cell-Titer Glo.
(D) Cotreatment of SUM159 cells with AZD6244 and foretinib enhances growth inhibition, as determined by Cell-Titer Glo.
(E) Cell counting confirms synergistic growth inhibition of combined AZD6244 and sorafenib treatment in SUM159 cells.
(F) Sorafenib inhibits AZD6244-mediated activation of RTKs. SUM159 cells were treated as indicated for 72 hr, and RTK Tyr phosphorylation was determined by
RTK antibody arrays.
(G) Cotreatment of SUM159 cells with AZD6244 and sorafenib enhances inhibition of ERK activity and primes cells for apoptosis. SUM159 cells were treated with
AZD6244 and/or sorafenib for 72 hr, and BIM, cyclin D1 expression, and ERK activity were determined by western blot.
(H) AZD6244 activation of ERK1/2 requires RTK and MEK activity. Inhibition of ERK activity in SUM159-R cells occurs after treatment with 50 mM AZD6244 or
cotreatment of 5 mM AZD6244 with 250 nM sorafenib.
(I) SUM159-R cells require AZD6244-induced RTK activity for drug resistance. SUM159-R cells treated with 250 nM sorafenib are growth arrested over 72 hr, as
determined by cell counts.
*p < 0.001. Error bars represent triplicate experiments ± SD. See also Figure S5 and Table S4.Kinome Reprogramming in the C3Tag TNBC GEMM
The genetically engineered C3Tag mouse model has a gene ex-
pression signature similar to human TNBC. To define AZD6244-
mediated kinome reprogramming in vivo, we harvested tumor
tissue before or after oral delivery of AZD6244. Figures 6A and S6
show increased expressionof PDGFRb in response toAZD6244 in
both the tumor cells and stroma of C3Tag tumors, demonstrating
in vivo induction of PDGFRb. Rapid degradation of c-Myc protein
and induction of PDGFRb was observed in 2 days and 7 days316 Cell 149, 307–321, April 13, 2012 ª2012 Elsevier Inc.AZD6244-treated tumors, consistentwith lossofc-Myc repression
ofRTKexpression (Figure 6B). AC3Tag-derived breast cancer cell
line (T2-C3Tag) isolated from the GEMM tumor responded to
AZD6244 with upregulation of PDGFRb and DDR1, confirming
the tumor cell response to MEK inhibitor (Figure 6C). Expression
of nondegradable c-Myc(T58A) in T2-C3Tag cells prevented the
induction of PDGFRb and DDR1, further indicating that proteaso-
mal degradation of c-Myc is responsible for RTK reprogramming
in C3Tag tumor cells (Figure 6D).
Profiling Kinome Response to Targeted Combination
Therapies in the C3Tag Mouse Model of TNBC
MIB/MS was then used to define the kinome response profile of
C3Tag tumors frommice treated with AZD6244, sorafenib, or the
combination of AZD6244 and sorafenib (Figure 6E). The MIB/MS
signatures of tumors continuously treated with AZD6244 or
sorafenib share some overlap but exhibit significant differences,
demonstrating drug-selective reprogramming of the kinome.
AZD6244-treated tumors have upregulation of RTKs PDGFRb,
DDR2, and CSF1R, as well as a number of tyrosine kinases
similar to the AZD6244 response in human TNBC cell lines.
Importantly, the escape of MEK2 and ERK1 from AZD6244 inhi-
bition was recapitulated in MIB/MS profiles of AZD6244-treated
C3Tag tumors. Sorafenib-treated tumors showed decreased
MIB binding of the previously reported sorafenib targets:
BRAF, PDGFRb, CSF1R, DDR1, DDR2, KIT, MLTK, and FRK
(Karaman et al., 2008). Both AZD6244- and sorafenib-treated
tumors showed increased MIB binding of cyclin-dependent
kinases, indicating that the tumors have circumvented the action
of the single agents to reenter cell-cycle progression. MIB/MS
profiling of tumors treated with the combination of AZD6244
and sorafenib showed reducedMIB binding of kinases activated
by AZD6244 treatment (Figure 6F). Sorafenib inhibited AZD6244-
mediated activation of RTKs PDGFRb, DDR2, and CSF1R,
as well as a number of intracellular Tyr kinases, including
JAK1. RTK-driven activation of MEK2-ERK1 was inhibited by
sorafenib in tumors, and loss of cyclin-dependent kinase binding
to MIBs was also observed, consistent with the combination of
AZD6244 and sorafenib arresting tumor growth (Figure 6G).
AZD6244 plus Sorafenib Causes Tumor Regression
After only 2 days of AZD6244 or sorafenib treatment, the expres-
sion of VEGFR2 and PDFGRb was increased along with in-
creased phosphorylation of RAF at Ser338, demonstrating RAF
activation (Figure 7A). The combination of AZD6244 and sora-
fenib reduced VEGFR2 and PDGFRb expression, suppressed
RAF activation, and synergistically inhibited reactivated ERK.
Figure 7B shows that the combination of AZD6244 and sora-
fenib blocked ERK activation and induction of PDGFRb in the
T2-C3Tag cell line. Cyclin B1 levels are also reduced by the
combination therapy, and a strong growth arrest was observed
in cells cotreated with AZD6244 and sorafenib, indicating that
AZD6244 sensitizes cells to sorafenib treatment (Figure 7C).
Our findings showed that the combination of AZD6244 and
sorafenib was significantly more effective in inhibiting ERK
activation in 2 days treated C3Tag mice and the C3Tag tumor
cell line. Therefore, C3Tag mice were allowed to develop tumors
and were then treated for 21 days with AZD6244 and/or sora-
fenib (Figures 7D and S7A). Sorafenib treatment alone had no
effect on tumor progression, whereas 30% of the AZD6244-
treated mice showed some tumor regression. In contrast, 77%
of mice treated with AZD6244 and sorafenib had tumor regres-
sion, demonstrating a significantly greater effect of the com-
bination therapy versus AZD6244 alone. TUNEL assays of the
tumors showed that the combination of AZD6244 and sorafenib
induced a strong apoptotic response in only 2 days of treat-
ment, in stark contrast with single drug treatment (Figures 7E
and S7B).DISCUSSION
We describe a novel approach to study the reprogramming of
protein kinase networks ‘‘en masse.’’ Our methods allowed the
isolation and analysis of protein kinases from cells and tumors
with 50%–60% of the expressed kinome assayed in a single
mass spectrometry run. Profiling MIB binding of kinases is
a highly sensitive method to simultaneously monitor activation
and inhibition of numerous kinases. This profiling technique
allows interrogation of kinases known by sequence but that
have been understudied due to lack of biologic or phenotypic
knowledge or reagent availability. An example of the latter is
the ability to distinguish changes in MEK1 and MEK2.
This technique identified a kinome response signature to the
selective MEK1/2 kinase inhibitor AZD6244. The only defined
substrates for MEK are ERK1 and 2, yet we observed changes
in activity of kinases in every subfamily of the kinome in response
to MEK inhibition. Kinome assessment showed a time-depen-
dent reprogramming that involved an early loss of ERK feedback
regulation of RAF and MEK, as well as increased MKP3 protein
stability. The increased expression of MKP3 functions to en-
hance ERK inactivation. In contrast, the loss of RAF and MEK
feedback inhibition would allow upstream activation of the
pathway. The time-dependent change in MIB binding of specific
RTKs such as PDGFRb and DDR1 was readily detected and
provided the critical experimental observation that MEK inhibi-
tion was driving the expression and activation of multiple
RTKs, each of which are capable of stimulating the RAF-MEK-
ERK pathway. Importantly, we identified c-Myc degradation as
a key mechanism mediating kinome reprogramming; preventing
proteasomal degradation of c-Myc inhibited the reprogramming
response. RNAi knockdown of ERK or c-Myc recapitulated the
MEK inhibitor-induced expression and Tyr phosphorylation of
several RTKs, demonstrating that ERK regulation of c-Myc
stability is critical in controlling the expression and activation of
specific kinases. The fact that multiple RTKs are activated in
response to MEK inhibition demonstrates the difficulty in using
single kinase inhibitors to arrest tumor progression.
In addition to c-Myc, inhibition of AKT and mTOR also causes
kinome reprogramming in different breast cancer subtypes
(Chandarlapaty et al., 2011; Rodrik-Outmezguine et al., 2011).
Whereas c-Myc functions as a repressor of PDGFRb, DDR1/2,
and VEGFR2 expression in claudin-low breast cancer, AKT has
been shown to negatively regulate FOXO-dependent expression
of HER3, IGF1R, and INSR in several breast cancer cell lines.
Inhibition of mTOR kinase activity leads to AKT inhibition and
subsequent RTK reprogramming (Rodrik-Outmezguine et al.,
2011). Differential kinome reprogramming is seen not simply
with targeting theMEK-ERK and AKT pathways but with tyrosine
kinase inhibitors as well. HER3 upregulation was shown to
play a major role in lapatinib resistance (Garrett et al., 2011),
and in lung cancer, MET amplification leads to gefitinib resis-
tance (Engelman et al., 2007).
Analysis of the ERK pathway in cells treated with AZD6244
showed a time-dependent rescue of BRAF/RAF, MEK2, ERK1,
and RSK1 binding to MIBs. We demonstrated that MIB binding
of these kinases is a function of their activation. The time course
of recovery parallels that of AZD6244-induced RTK expression.Cell 149, 307–321, April 13, 2012 ª2012 Elsevier Inc. 317
Figure 6. AZD6244-Mediated Kinome Reprogramming in C3Tag Mouse Model of TNBC
(A) PDGFRb is induced in C3Tag tumors after 2 days AZD6244 treatment, as shown by anti-PDGFRb immunofluorescence.
(B) AZD6244 treatment of C3Tag mice for 2 and 7 days causes c-Myc degradation and induced PDGFRb expression, as shown by western blot.
(C) Tumor-derived C3Tag cell line shows AZD6244-mediated c-Myc loss and induction of RTKs. T2-C3Tag cells were treated with AZD6244, and RTK
reprogramming was determined by western blot.
(D) Expression of c-Myc(T58A) in T2-C3Tag cells suppresses AZD6244-mediated RTK reprogramming. T2-C3Tag cells stably expressing vector or human
c-Myc(T58A) were treated with AZD6244 for 24 hr and were analyzed by western blot.
(E) MIB/MS profile of C3Tag tumors in response to AZD6244 for 28 days, sorafenib for 26 days, or combined AZD6244 and sorafenib for 26 days show distinct
kinome responses. The line graphs show iTRAQ-determined quantitative changes in MIB binding as a ratio of inhibitor/untreated. Ratio < 1 denotes decreased
MIB binding, and > 1 denotes increased MIB binding of kinases in treated versus control tumors.
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Figure 7. Combination of AZD6244 and Sorafenib Causes Apoptosis and Tumor Regression in C3Tag TNBC Mouse Model
(A) AZD6244 (20 mg/kg) or sorafenib (30 mg/kg) fed in chow results in ERK activation after 2 days of treatment in C3Tag GEMM, whereas cotreatment with
AZD6244 and sorafenib inhibits RTK-mediated ERK activation. RTK reprogramming was monitored in tumors treated with AZD6244 and/or sorafenib relative to
untreated tumors by western blot.
(B) Sorafenib inhibits AZD6244-dependent reactivation of ERK, promoting c-Myc degradation and loss of cyclin B1 expression in T2-C3Tag cells. T2-C3Tag cells
were treated for 24 hr and were analyzed by western blot.
(C) AZD6244 and sorafenib synergize to inhibit cell growth in C3Tag cell line. T2-C3Tag cells were treated with AZD6244 and sorafenib, alone or in combination,
and cell growth was determined by cell counting (*p < 0.001; quadruplicate experiments).
(D) Cotreatment of C3Tag mice with AZD6244 and sorafenib for 21 days causes significant tumor regression compared to AZD6244 alone. C3Tag mice were
treated with AZD6244 (20 mg/kg), sorafenib (30 mg/kg), or the combination of AZD6244 and sorafenib and were compared to untreated tumors. Percent change
in tumor volume of drug treated relative to untreated is shown (*Wilcoxon p = 0.007).
(E) Increased apoptosis of C3Tag mouse tumors following cotreatment with AZD6244 and sorafenib. Apoptosis in C3Tag tumors treated for 2 days was
determined by TUNEL staining (shown in red; DAPI is grayscale).
See also Figure S7.The C3Tag tumor shows a comparable increase in MEK2 and
ERK1 binding after AZD6244 treatment, mimicking the reprog-
ramming response observed in SUM159 cells. Published work
with a similar MEK inhibitor, GSK1120212, which binds to the
MEK allosteric regulatory site (as does AZD6244) provides
insight into how MEK2 escapes inhibition (Gilmartin et al.,
2011). MEK phosphorylated at the activation loop serines has
a 20-fold lower affinity for GSK1120212 than nonphosphorylated
MEK, effectively alleviating allosteric site inhibition of MEK.
Because ERK activity is increasing over time, MEK1 would be
feedback phosphorylated at its negative regulatory site Thr292,
preventing MEK1 reactivation even in the setting of RTK reprog-(F) AZD6244 plus sorafenib inhibits AZD6244-induced kinome response in C3T
AZD6244-responsive kinases following cotreatment with sorafenib are shown in
(G) Cotreatment of C3Tag mice with AZD6244 and sorafenib prevents upregula
PDGFRb. These kinases were selected from (E) with a > 1.5-fold reduction in MIB
sorafenib.
See also Figure S6.ramming; MEK2, however, lacks this regulatory site and selec-
tively escapes inhibition. This suggests a unique paradigm of
activation of an upstream signaling pathway increasing the
IC50 of an inhibitor for a target kinase.
Inmany tumor types Tyr kinases aremolecular drivers of trans-
formation and also play a major role in resistance to therapy.
Claudin-low SUM159 cells and the C3Tag breast cancer
GEMM were remarkably similar in response to AZD6244, with
induction and activation of PDGFRb, VEGFR2, CSFR1, DDR1/2,
and AXL. The claudin-low MDA-MB-231 cell line was somewhat
less responsive but still showed the induction of PDGFRb, DDR1,
and DDR2 and activation of AXL with AZD6244 treatment. RNAiag tumors, as identified by MIB/MS. Changes in MIB binding (>1.5 fold) of
yellow.
tion of kinases observed by AZD6244 treatment alone, including CDKs and
binding between AZD6244 treatment alone and cotreatment with AZD6244 and
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knockdown of the different RTKs indicated that each kinase
contributed to the survival response of SUM159 and MDA-MB-
231 cells. Given the repertoire of RTKs whose expression and
activity is induced with AZD6244 treatment, we predicted that
the combination therapy of sorafenib and AZD6244 would
‘‘broaden’’ the kinase targeting sufficiently to produce significant
therapeutic benefit. The combination therapy increased apo-
ptosis and tumor regression significantly compared to either
drug alone in the C3Tag TBNC GEMM.
We identified AZD6244-induced RTKs (and Ser/Thr kinases)
using a combination of MIB/MS and immunoblotting of cell lines
and C3Tag tumors. We created a signature of therapeutic
resistance, allowing a rational prediction of combinatorial thera-
pies. This approach can be extended to human tumors using
so-called ‘‘window trials’’ in which a patient is treated with a
targeted agent prior to surgery and their tumor analyzed at exci-
sion for kinome-resistance signatures. Importantly, we have
shown that the kinome response is unique for inhibitors targeting
different kinases, and the response of different tumor types to
a common inhibitor may also vary. Thus, this systems kinome
approach can be applied to help define patterns of resistance
for a variety of drugs and biopsy-accessible tumor types.
EXPERIMENTAL PROCEDURES
Cell Culture
MDA-MB-231 and T2-C3Tag cells were grown in DMEM/F12 supplemented
with 10% FBS. SUM159 cells were grown in DMEM/F12 supplemented with
5% FBS, 1 mg/ml hydrocortisone, and 5 mg/ml insulin. SUM159-R cells were
continually grown in the presence of 5 mM AZD6244. For SILAC labeling,
cells were grown for five doublings in arginine- and lysine-depleted media
(as above) supplemented with either unlabeled L-arginine (42 mg/l) and




6) (Cambridge Isotope Laboratories). Proliferation was quanti-
fied by Cell-Titer Glo Luminescent Cell Viability Assay (Promega). Media con-
taining kinase inhibitors was replaced daily.
MIB Chromatography
Cells and tumors were harvested as previously described (Oppermann et al.,
2009). In brief, lysates were brought to 1 M NaCl and passed through columns
of inhibitor-conjugated beads (Bisindoylmaleimide-X, SB203580, Lapatinib,
Dasatinib, Purvalanol B, VI16832, PP58) to isolate protein kinases from
the lysates (see Extended Experimental Procedures for MIB preparation).
Kinase-bound inhibitor beads were washed with high- and low-salt buffers
and 0.1% SDS before elution in 0.5% SDS solution in high heat. Proteins
were purified using chloroform/methanol extraction, resuspended in 50 mM
ammonium bicarbonate (pH 8) or 50 mM HEPES (pH 8) for SILAC or iTRAQ,
respectively. Samples were digested overnight at 37Cwith sequencing grade
modified trypsin (Promega). iTRAQ labeling of digested peptides was carried
out using iTRAQ 4-plex reagent (AB SCIEX) for 2 hr at room temperature in
the dark. Peptides were fractionated withMini SCX Spin Columns and cleaned
with PepClean C18 Spin Columns (Thermo Scientific) before separation by
a Tempo LC MALDI Spotting System.
MS Analysis
MS and MS/MS data were acquired with a MALDI TOF/TOF 5800 (ABSCIEX)
and analyzed by ProteinPilot Software Version 3.0 (ABSCIEX) with a
UniProtKB/Swiss-Prot database. Proteins were accepted when R 1 unique
peptide was identified at 99% confidence. Peptide quantitation by ProteinPilot
was performed using the Pro Group Algorithm, and quant ratios are bias
corrected. All MIB/MS kinome response profiles can be found in Table S5.
MIB/MS analysis with cell lines was done in two to three independent experi-
ments. A set of three independent experiments using SILAC labeled SUM159320 Cell 149, 307–321, April 13, 2012 ª2012 Elsevier Inc.cells treated with AZD6244 or DMSO was used to assess statistical signifi-
cance and reproducibility of MIB/MS (Extended Experimental Procedures
and Table S6).
Western Blotting and RTK Arrays
Western blotting and RTK array analyses were performed as previously
described (Amin et al., 2010). Detailed methods and antibodies are provided
in Extended Experimental Procedures.
qRT-PCR
RNA was isolated from cell lines or murine tumors using the RNeasy Plus Mini
Kit (QIAGEN). qRT-PCR was performed on diluted cDNA with the Applied
Biosystems 7500 Fast Real-Time PCR System and inventoried TaqMan
Gene Expression Assays.
In Vivo Tumorigenesis Experiments
Animal handling and procedures were approved by the UNC Institutional
Animal Care and Use Committee and followed the NIH guidelines. Male
C3Tag mice were bred with wild-type females to produce experimental
offspring. Treatment began the same day that a palpable mass was found.
Drugs were incorporated into chow, and food was provided ab libitum. Tumor
size was assessed twice weekly by caliper measurements of tumor areas
((width)2 3 length)/2 for 21 days. Percent change of tumor volume was calcu-
lated using (final volume – initial Volume)/initial volume and graphed using R
(http://www.r-project.org/). Tumors at harvest were halved and either snap
frozen in liquid nitrogen and stored at 80C or placed in neutral buffered
10% formalin solution.
Human Breast Tissue Procurement
All human breast tissue was obtained from the Tissue Procurement Facility in
compliance with the laws and institutional guidelines as approved by the UNC
IRB committee. Clinical specimens were phenotyped by gene expression
analysis in the lab of CMP.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and six tables and can be found with this article online at doi:10.1016/
j.cell.2012.02.053.
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